Bristol-Myers Squibb News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

18.09.13	Pipeline Developments, Product Recalls, Clinical Trial Results, Recognitions, and New Appointments - Research Report on Johnson & Johnson, Amgen, Regeneron, UnitedHealth, and Bristol-Myers (PR Newswire)
17.09.13	Pre-Market Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Health Solutions Inc., and Allergan Inc. (PR Newswire)
17.09.13	NDA Updates, Signed Agreements, Awarded Patents, and Clinical Study Results - Research Report on Merck, Bristol-Myers Squibb, Amarin, GlaxoSmithKline, and Sanofi (PR Newswire)
12.09.13	Bristol-Myers: Yervoy Study's Primary Endpoint Of Overall Survival Did Not Meet (RTTNews)
09.09.13	Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly, and GSK (PR Newswire)
03.09.13	BMY, Pfizer Records Consistent Results In Sub-analysis Of Eliquis Vs. Warfarin (RTTNews)
02.09.13	Bristol-Myers: Onglyza Achieves Primary Safety Endpoint - Quick Facts (RTTNews)
31.08.13	Bristol-Myers,Pfizer Report Results Of Post-hoc Subanalysis From ARISTOTLE Trial (RTTNews)
26.08.13	Critical Alerts For Google, Bristol Myers, Expedia, Morgan Stanley, and Travelers Released By InvestorsObserver (PR Newswire)
12.08.13	Early Briefing and Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Allergan Inc., and Endo Health Solutions Inc. (PR Newswire)
09.08.13	Rubber and Plastics Companies Declare Quarterly Results, Dividends - Research Report on Goodyear Tire & Rubber, Carlisle, MeadWestvaco, Bemis Company, and Berry Plastics Group (PR Newswire)
06.08.13	Positive Opinions, Solid Margins, Agreements, and Clinical Trials to Boost Run Rate of Drug Manufacturers - Research Report on Johnson & Johnson, Pfizer, Merck, Bristol-Myers Squibb, and Lilly (PR Newswire)
30.07.13	Regulatory Approvals, Product Launches, and Steady Sales Show Signs of Growth - Research Report on Johnson & Johnson, Bristol-Myers Squibb, Actavis, Edwards Lifesciences, and Health Net (PR Newswire)
25.07.13	Bristol-Myers Profit Slides On Generic Rivals; Trims 2013 Outlook (RTTNews)
25.07.13	Critical Alerts For Morgan Stanley, Hanesbrands, Bristol Myers, Expedia, and D R Horton Released By InvestorsObserver (PR Newswire)
25.07.13	Bristol-Myers Q2 Adj. Profit Matches View; Cuts FY13 Profit View - Quick Facts (RTTNews)
25.07.13	Earnings Watch For July 25 (MMM, CCE, GM, AMZN, SBUX, BMY, DHI) (RTTNews)
17.07.13	Reports: Pfizer, Amgen Among Five Potential Suitors For Onyx (RTTNews)
11.07.13	RMTI Cruises Ahead, ALNY, CELG Touch New Highs, BIOD Progresses (RTTNews)
11.07.13	FDA Accepts Eliquis SNDA For Review - Quick Facts (RTTNews)
04.03.10	Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment Community (Businesswire)
02.03.10	Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as Chairman (Businesswire)
02.03.10	FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients (Businesswire)
28.01.10	Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009 (Businesswire)
25.01.10	European Commission Approves ORENCIA® (abatacept) in Combination with Methotrexate for Children with Moderate to Severe Polyarticular Juvenile Idiopathic Arthritis (pJIA) (Businesswire)
02.12.09	New Data on Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology (Businesswire)
20.11.09	U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years) (Businesswire)
31.10.09	BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis (Businesswire)
23.10.09	Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer (Businesswire)
22.10.09	Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter (Businesswire)
20.10.09	New Data Describe Safety of Subcutaneous Administration of ORENCIA® (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis (Businesswire)
19.10.09	ORENCIA® (abatacept) Demonstrated Sustained Clinical Response in a Study of Adult Patients with Moderate to Severe Early Rheumatoid Arthritis (Less Than Two Years Duration) (Businesswire)
23.07.09	Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb (Businesswire)
12.06.09	ORENCIA® (abatacept) DEMONSTRIERT KONSISTENTE SICHERHEIT UND WIRKSAMKEIT ÜBER 7 JAHRE HINWEG (Businesswire)
12.06.09	ORENCIA® (abatacept) DEMONSTRATES CONSISTENT SAFETY AND EFFECTIVENESS OVER 7 YEARS (Businesswire)
14.05.09	SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate Cancer (Businesswire)
27.01.09	Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb (Businesswire)
06.11.08	Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal (Businesswire)
02.11.08	New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B (Businesswire)
28.10.08	Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis (Businesswire)
23.10.08	Bristol-Myers Squibb Continues Excellent Financial Performance Led By Double-Digit Global Net Sales Growth and Strong Earnings Results (Businesswire)
06.10.08	Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner (Businesswire)
01.10.08	U.S. Food & Drug Administration Approved the use of REYATAZ(R) (atazanavir sulfate) Boosted with Ritonavir, in Combination Therapy, for Previously Untreated HIV-1 Infected Adult Patients (Businesswire)
01.10.08	Thirteen Advocacy Groups Collaborate on New Online Resource Dedicated to Patients with Advanced Breast Cancer (Businesswire)
13.08.08	ADDING MULTIMEDIA NJ, CT, NY & MD School Districts Join Program That Teaches High School Students How Medicines Are Made (Businesswire)
12.06.08	ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis (Businesswire)
13.05.08	Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease (Businesswire)
24.04.08	Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company (PR Newswire)
17.12.07	Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million (PR Newswire)
11.12.07	Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

mehr

14:22		Pharma-Aktien im Fokus: Merck, Roche & Co. mit positiven Analystenprognosen
31.01.25		Verluste in New York: NASDAQ Composite schlussendlich in der Verlustzone
31.01.25		Handel in New York: S&P 500 zeigt sich zum Handelsende schwächer
31.01.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
31.01.25		Zurückhaltung in New York: NASDAQ 100 verliert letztendlich
31.01.25		Aufschläge in New York: Am Nachmittag Pluszeichen im S&P 500
31.01.25		Handel in New York: NASDAQ 100 notiert am Freitagnachmittag im Plus
31.01.25		Pluszeichen in New York: NASDAQ Composite legt nachmittags zu